Revenue from Contracts with Customers (Tables)

9 Months Ended

Sep. 30, 2021

Revenue From Contract With Customer [Abstract]

Product and Product-Related Service Revenue from Sale of Instruments and Consumables

Product and Product-related Services Revenue

The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the three and nine months ended September 30, 2021 and 2020 as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Product revenue:
Instruments	$	407,130	$	71,742	$	1,028,348	$	563,396
Consumables		793,542		764,605		2,265,894		2,091,848
Total product revenue		1,200,672		836,347		3,294,242		2,655,244
Product-related services revenue:
Custom RUO assay design		—		238,502		48,350		1,210,968
RUO sample processing		1,319,738		626,219		2,687,168		1,551,519
Total product-related services revenue		1,319,738		864,721		2,735,518		2,762,487
Total product and product-related services revenue	$	2,520,410	$	1,701,068	$	6,029,760	$	5,417,731

Schedule of Collaborative Development Services

The Company enters into collaborative development services agreements with biopharmaceutical companies for the development of NGS-based companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. These collaborative development services agreements may generate upfront fees, and in some cases subsequent milestone payments that may be earned upon completion of certain product development milestones or activities. The Company follows ASC 606 and ASC 808 to determine the appropriate recognition of revenue under its collaborative research, development and commercialization agreements. Because each SOW had an expected duration of one year or less, the Company elected the practical expedient in ASC 606-10-50-14(a) not to disclose information about its remaining performance obligations for each SOW.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Collaborative development services	$	—	$	76,030	$	—	$	548,135

Schedule of Changes in Contract Liability

Changes in the Company’s contract liability were as follows as of the dates indicated:

	Product Revenue			Custom RUO Assay Design		Sample Processing			Total Contract Liability
Balance at January 1, 2021	$	103,580		$	-	$	93,884		$	197,464
Deferral of revenue		261,100			—		525,899			786,999
Recognition of deferred revenue		(198,438	)		—		(535,501	)		(733,939	)
Balance at September 30, 2021	$	166,242		$	—	$	84,282		$	250,524

	Product Revenue			Custom RUO Assay Design			Sample Processing			Total Contract Liability
Balance at January 1, 2020	$	95,148		$	66,216		$	438,090		$	599,454
Deferral of revenue		335,265			459,385			77,104			871,754
Recognition of deferred revenue		(325,181	)		(525,601	)		(95,670	)		(946,452	)
Balance at September 30, 2020	$	105,232		$	—		$	419,524		$	524,756